Cyclohexane Derivatives with Benzoheterocycle Fragments for D3 Selectivity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cyclohexane derivatives for treating mental disorders, such as schizophrenia, have limitations in selectivity for dopamine D2/D3 receptors, leading to side effects like extrapyramidal reactions, and there is a need for compounds with improved affinity and selectivity for these receptors to enhance treatment efficacy and safety.
Innovation Solution
Development of cyclohexane derivatives with specific structural modifications, including the incorporation of benzoheterocycle fragments like benzothiophene and benzisothiazole, which exhibit high affinity for the dopamine D3 receptor and low affinity for the D2 receptor, reducing side effects and improving therapeutic outcomes for schizophrenia and other neuropsychiatric disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If cyclohexane derivatives with (thio) carbamoyl side chain are used to modulate dopamine receptors, then affinity for dopamine D2/D3 receptors is improved, but selectivity between D2 and D3 receptors deteriorates, leading to side effects like extrapyramidal reactions
Solution Approach 1:
The patent applies local quality by introducing specific substituents at defined positions on the cyclohexane ring (positions 2 and 6) with particular stereochemistry. The compound features a carbamoyl group at one position and specific substituents (halogen, alkyl, alkoxy, or hydroxyl groups) at other positions, creating localized functional regions that differentially interact with D3 versus D2 receptors. This spatial arrangement of functional groups provides high D3 selectivity while maintaining overall dopamine receptor affinity, thereby improving therapeutic reliability while reducing harmful side effects.
2Reliability
If Cariprazine is used to treat schizophrenia with D2/D3 antagonism and 5-HT1A partial agonism, then treatment efficacy is improved, but selectivity to D3 receptor deteriorates (only 5% probability of avoiding cathisophobia and extrapyramidal reaction at 3mg dose)
Solution Approach 1:
The patent applies parameter changes by systematically varying the substituent parameters at positions 2 and 6 of the cyclohexane ring, including different halogen atoms (F, Cl, Br, I), different alkyl chain lengths (C1-C6), and different functional groups (alkoxy, hydroxyl). These parameter variations are optimized to achieve a specific binding profile with dopamine receptors, particularly enhancing D3 receptor selectivity. The stereochemical parameters (cis/trans isomers) are also controlled to fine-tune the affinity and selectivity ratios, thereby maintaining treatment efficacy while minimizing side effects through precise molecular parameter optimization.
3Reliability
If cyclohexane derivatives are structurally modified to achieve higher D3 receptor selectivity, then selectivity ratio D3/D2 is improved, but molecular complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the molecule into distinct functional segments: the core cyclohexane ring structure, the carbamoyl side chain segment, and the substituent segments at positions 2 and 6. Each segment serves a specific function in receptor binding and selectivity. This modular segmentation allows for systematic optimization of D3/D2 selectivity by independently modifying substituent parameters without completely redesigning the entire molecule, thereby managing molecular complexity while achieving high selectivity ratios.
Data Source
AI summary
Provided are a cyclohexane derivative as shown by formula IB or a stereoisomer or a salt thereof, and the preparation and use thereof. The cyclohexane derivative has a high affinity for D3 receptors and 5-hydroxytryptamine, has a lower affinity for D2 receptors, shows a high selectivity for D3/D2 receptors, and can be used as a therapeutic drug against neuropsychiatric diseases; and the preparation method thereof is simple and easy.